

Please try another search
For the nine months ended 31 December 2021, Acasti Pharma Inc revenues decreased from $81K to $0K. Net loss decreased 58% to $5.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Change in fair value of warrant liabilit increase from $420K to $4.9M (income), Impairment of Intangible assets decrease from $3.7M (expense) to $0K.
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0.12 |
Gross Profit | 0 | 0.07 | ||
Operating Income | -4.47 | -3.57 | -3.15 | -2.3 |
Net Income | -3.78 | 0.98 | -3.12 | -5.65 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 114.23 | 119.8 | 60.45 | 62.46 |
Total Liabilities | 3.17 | 5.59 | 7 | 6.8 |
Total Equity | 111.06 | 114.2 | 53.46 | 55.66 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -14.09 | -9.51 | -3.4 | -14.32 |
Cash From Investing Activities | -3.53 | -4.09 | -6.93 | -9.86 |
Cash From Financing Activities | 0 | 0 | 0 | 59.49 |
Net Change in Cash | -17.93 | -14.01 | -9.97 | 36.7 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review